玛巴洛沙韦:首个靶向于Cap-依赖性核酸内切酶的抗流感药物  

Baloxavir marboxil:the first anti-influenza drug targeting Cap-dependent endonuclease

作　　者：周姝含 胡长平 罗平 ZHOU Shu-han;HU Chang-ping;LUO Ping(Department of Pharmacology,Xiangya School of Pharmaceutical Sciences,Central South University,Changsha 410078;Department of Pharmacy,Xiangya Hospital,Central South University,Changsha 410008)

机构地区：[1]中南大学湘雅药学院药理学系,长沙410078 [2]中南大学湘雅医院药学部,长沙410008

出　　处：《中南药学》2024年第7期1822-1830,共9页Central South Pharmacy

基　　金：国家自然科学基金资助项目(No.82173817,No.82241025);长沙市自然科学基金(No.kq2208366)。

摘　　要：玛巴洛沙韦是首个Cap-依赖性内切酶抑制剂,通过抑制流感病毒RNA聚合酶酸性蛋白亚基内切酶活性,从而抑制流感病毒的复制。玛巴洛沙韦于2022年8月通过美国食品药品监督管理局(FDA)审批,在临床上用于治疗5岁及以上、流感症状不超过48 h的急性无并发症流感患者,并于2023年3月获得中国国家药品监督管理局正式批准。临床试验表明,玛巴洛沙韦具有单剂量给药、安全性高等优势,将成为儿童流感患者的替代药物。Baloxavir marboxil is the first Cap-dependent endonuclease inhibitor,which inhibits the replication of influenza virus by inhibiting the activity of influenza RNA polymerase acidic protein subunit endonuclease.It was approved by the U.S.Food and Drug Administration in August 2022 for acute uncomplicated influenza patients aged 5 years and older with symptoms less than 48 hours.It was officially approved by the National Medical Products Administration of China in March 2023.Clinical trials have shown that baloxavir marboxil,with its advantages of single dose administration and high safety,may become an alternative for drug-resistant pediatric patients.

关 键 词：玛巴洛沙韦 流行性感冒 Cap-依赖性核酸内切酶 抗流感药物 儿童 

分 类 号：R978.7[医药卫生—药品]